[HTML][HTML] Therapeutic monoclonal antibody therapies in chronic autoimmune demyelinating neuropathies

C Briani, A Visentin - Neurotherapeutics, 2022 - Elsevier
Autoimmune diseases of the peripheral nervous system have so far been treated mainly with
exogenous high-dose intravenous immunoglobulins (IVIg), that act through several …

Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies

R Roskoski Jr - Pharmacological Research, 2021 - Elsevier
The discovery of the phosphatidylinositol 3-kinase (PI 3-kinase) pathway was a major
advance in understanding eukaryotic signal transduction. The high frequency of PI 3-kinase …

[HTML][HTML] The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation

A Visentin, L Bonaldi, GM Rigolin, FR Mauro… - …, 2022 - ncbi.nlm.nih.gov
Complex karyotype (CK) at chronic lymphocytic leukemia (CLL) diagnosis is a negative
biomarker of adverse outcome. Since the impact of CK and its subtypes, namely type-2 CK …

Neurological complications of conventional and novel anticancer treatments

P Alberti, A Salvalaggio, AA Argyriou, J Bruna… - Cancers, 2022 - mdpi.com
Simple Summary Cancer survivors can experience neurological complications after
exposure to anticancer therapy. Chemotherapy-induced peripheral neurotoxicity (CIPN) …

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)

DA Sabbah, R Hajjo, SK Bardaweel… - Expert Opinion on …, 2021 - Taylor & Francis
ABSTRACT Introduction: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian
target of rapamycin (PI3K/AKT/mTOR) signaling pathway plays a central role in regulating …

Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS

R Roskoski Jr - Pharmacological Research, 2021 - Elsevier
Abstract RAS proteins (HRAS, KRAS, NRAS) participate in many physiological signal
transduction processes related to cell growth, division, and survival. The RAS proteins are …

PI3Kδ inhibitors as immunomodulatory agents for the treatment of lymphoma patients

C Tarantelli, L Argnani, PL Zinzani, F Bertoni - Cancers, 2021 - mdpi.com
Simple Summary This review focuses on the effects that a class of drugs, PI3Kδ inhibitors,
used for the treatment of patients with lymphoma can have not on the neoplastic cells but on …

Targeting protein kinases in blood cancer: focusing on CK1α and CK2

Z Spinello, A Fregnani, L Quotti Tubi, L Trentin… - International journal of …, 2021 - mdpi.com
Disturbance of protein kinase activity may result in dramatic consequences that often lead to
cancer development and progression. In tumors of blood origin, both tyrosine kinases and …

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: a real-life CLL campus study

A Visentin, FR Mauro, G Catania, A Fresa… - Frontiers in …, 2022 - frontiersin.org
One of the main issues in the treatment of patients with chronic lymphocytic leukemia (CLL)
deals with the choice between continuous or fixed-duration therapy. Continuous ibrutinib …

Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders?

A Visentin, M Puthenparampil… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Bruton's tyrosine kinase (BTK) is a multifaceted player of the immune system
which has been involved in the survival of hematological malignancies but also in the …